Holen Sie sich die Stockscreener-App
4.52
0.66%
-0.03
Handel nachbörslich:
4.40
-0.12
-2.65%
Schlusskurs vom Vortag:
$4.55
Offen:
$4.54
24-Stunden-Volumen:
42,000
Relative Volume:
0.14
Marktkapitalisierung:
$13.92M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-29.77M
KGV:
-0.2955
EPS:
-15.2954
Netto-Cashflow:
$-24.23M
1W Leistung:
+6.10%
1M Leistung:
+18.02%
6M Leistung:
-68.11%
1J Leistung:
-89.26%
1-Tages-Spanne:
$4.35
$4.54
1-Wochen-Bereich:
$4.2601
$5.1497
52-Wochen-Spanne:
$3.13
$91.25
Moleculin Biotech Inc Stock (MBRX) Company Profile
Firmenname
Moleculin Biotech Inc
Sektor
Branche
Telefon
713-300-5160
Adresse
5300 MEMORIAL DRIVE, HOUSTON, TX
Vergleichen Sie MBRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
4.52 | 14.01M | 0 | -29.77M | -24.23M | -15.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-09 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-02-12 | Herabstufung | Maxim Group | Buy → Hold |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
Moleculin Biotech Inc Aktie (MBRX) Neueste Nachrichten
Aug Intraday: Can Moleculin Biotech Inc maintain sales growthTrade Ideas & High Accuracy Swing Trade Signals - baoquankhu1.vn
Will Moleculin Biotech Inc. benefit from geopolitical trendsRate Hike & Smart Investment Allocation Insights - mfd.ru
Moleculin Biotech Updates Investors with New Corporate Presentation - TipRanks
Aug Spikes: What are Moleculin Biotech Incs earnings expectations2025 Geopolitical Influence & Safe Entry Zone Identification - baoquankhu1.vn
New brain cancer trial tests WP1066 plus radiation in glioblastoma - Stock Titan
MBRXMoleculin Biotec Latest Stock News & Market Updates - Stock Titan
Moleculin’s Annamycin shows no cardiotoxicity in cancer trials By Investing.com - Investing.com Nigeria
Moleculin’s Annamycin shows no cardiotoxicity in cancer trials - Investing.com
Moleculin Highlights Non-Cardiotoxic Profile of Lead Annamycin Drug - TipRanks
Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects - The Manila Times
Moleculin Biotech, Inc. Reports No Cardiotoxicity in Annamycin Trials - TradingView — Track All Markets
Moleculin Biotech, Inc. Reports No Evidence of Cardiotoxicity for Annamycin Across Five Clinical Trials - Quiver Quantitative
Here's Why Moleculin Biotech (MBRX) Is a Great 'Buy the Bottom' Stock Now - MSN
Moleculin expects first MIRACLE trial data readout in Q1 2026 By Investing.com - Investing.com Nigeria
Moleculin Biotech Inc. (MBRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Moleculin Biotech (MBRX) Readies Annamycin for Major Milestones in 2026 - GuruFocus
Moleculin expects first MIRACLE trial data readout in Q1 2026 - Investing.com
Moleculin Biotech advances Annamycin AML Phase 3 program - TipRanks
Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs - The Manila Times
Moleculin Biotech, Inc. Announces Milestones and Upcoming Unblinding for MIRACLE Trial in Acute Myeloid Leukemia and New Pancreatic Cancer Initiatives - Quiver Quantitative
Moleculin accelerates outlook into 2026 with first pivotal trial unblinding on track, global trial expansion, and multiple externally/IIT funded clinical programs - marketscreener.com
Moleculin Biotech, Inc. Accelerates 2026 Outlook with Key Clinical Trials - TradingView
Experimental chemo aiming to spare the heart nears key 2026 trial test - Stock Titan
Moleculin Biotech prices $5.9M public offering; shares down about 47% - MSN
AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week - MSN
Buy Signal: Why Moleculin Biotech Inc. stock could rally in 20252025 Stock Rankings & Weekly Chart Analysis and Trade Guides - Улправда
What technical charts say about Moleculin Biotech Inc. stockGap Up & Reliable Breakout Stock Forecasts - Улправда
Why retail investors favor Moleculin Biotech Inc. stockEarnings Miss Alerts & Free Fast Track Wealth Growth - ulpravda.ru
Moleculin Biotech, Inc.Common Stock (Nasdaq:MBRX) Stock Quote - FinancialContent
Why Moleculin Biotech Inc. stock is considered a top pickMarket Insider Reports & Budget Friendly Trading Strategies - Улправда
Moleculin Biotech regains Nasdaq listing compliance - marketscreener.com
Moleculin Biotech Regains Compliance With Nasdaq Listing Requirements - TipRanks
Moleculin Biotech Regains Nasdaq Compliance - TradingView
Why Moleculin Biotech Inc. stock remains a top recommendation2026 world cup usa national team round of 32 midfield engines counter attacking tactical prediction breakdown - Улправда
Moleculin shares rise 6% as enrollment nears key milestone in AML trial - MSN
Moleculin Biotech’s Wild Ride: Is Tiny-Cap MBRX the Next Viral Moonshot or Total Trap? - AD HOC NEWS
MBRX stock touches 52-week low at $1.46 amid sharp yearly decline - MSN
Moleculin Biotech enters inducement offer agreements - MSN
Moleculin Biotech begins dosing subjects in combination therapy trial for AML - MSN
Moleculin Biotech amends warrants and reports stockholders’ equity above $10 million - Investing.com Nigeria
Moleculin Biotech amends warrants and reports stockholders’ equity above $10 million By Investing.com - Investing.com South Africa
Moleculin Biotech Amends Warrants to Boost Nasdaq Compliance - TipRanks
Moleculin Biotech Signs Warrant Amendment Agreements With Holders of Series E, F and G Warrants - TradingView — Track All Markets
Moleculin Biotech amends warrants to boost Nasdaq compliance - MSN
Moleculin Biotech shares slide after release of pediatric brain tumor trial data - MSN
Will Moleculin Biotech Inc. stock rally after Fed decisions2025 Volatility Report & Long Hold Capital Preservation Tips - Улправда
Will Moleculin Biotech Inc. stock split attract more investorsMarket Performance Report & Safe Capital Growth Plans - Улправда
Moleculin Biotech Earnings Notes - Trefis
Moleculin Biotech (LTS:0K2H) EV-to-OCF : -0.07 (As of Dec. 19, 2025) - GuruFocus
How risky is Moleculin Biotech Inc. (MOL) stock compared to peersJuly 2025 Spike Watch & Target Return Focused Picks - DonanımHaber
Finanzdaten der Moleculin Biotech Inc-Aktie (MBRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.09%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):